Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16O6 |
Molecular Weight | 316.306 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(COc1ccc(cc1)C(=O)O)COc2ccc(cc2)C(=O)O
InChI
InChIKey=VBISQLWPGDULSX-UHFFFAOYSA-N
InChI=1S/C17H16O6/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21/h2-9H,1,10-11H2,(H,18,19)(H,20,21)
DescriptionCurator's Comment:: description was created based on several sources, including:
http://arborpharma.com/docs/201241r1-gliadel-pi.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7948590 | https://www.ncbi.nlm.nih.gov/pubmed/1350734
Curator's Comment:: description was created based on several sources, including:
http://arborpharma.com/docs/201241r1-gliadel-pi.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7948590 | https://www.ncbi.nlm.nih.gov/pubmed/1350734
BENZOIC ACID, 4,4'-(1,3-PROPANEDIYLBIS(OXY))BIS- (CPP-BIS) is a building block for polyanhydrides, which is a class of bioerodible polymer containing drug delivery applications. The polyanhydride copolymer system which currently enjoys the most widespread interest in its medical applications employs the monomers sebacic acid (SA) and CPP-BIS (Polifeprosan). Polifeprosan is a biodegradable copolymer used to control the release of carmustine in GLIADEL Wafer. GLIADEL Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent. GLIADEL Wafer is indicated in newly-diagnosed high-grade malignant glioma patients and in recurrent glioblastoma multiforme. Most common adverse reactions of GLIADEL Wafer are cerebral edema, asthenia, nausea, vomiting, constipation, wound healing abnormalities and depression.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3880353
Curator's Comment:: http://www-heparin.rpi.edu/main/files/papers/14.pdf | https://www.ncbi.nlm.nih.gov/pubmed/1350734
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Gliadel Wafer Approved UseGLIADEL® Wafer is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. GLIADEL® Wafer is indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Launch Date1.0460448E12 |
|||
Primary | Gliadel Wafer Approved UseGLIADEL® Wafer is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. GLIADEL® Wafer is indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Launch Date1.0460448E12 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1XMW35DTHB
Created by
admin on Sat Jun 26 01:54:31 UTC 2021 , Edited by admin on Sat Jun 26 01:54:31 UTC 2021
|
PRIMARY | |||
|
3753-81-9
Created by
admin on Sat Jun 26 01:54:31 UTC 2021 , Edited by admin on Sat Jun 26 01:54:31 UTC 2021
|
PRIMARY | |||
|
68610
Created by
admin on Sat Jun 26 01:54:31 UTC 2021 , Edited by admin on Sat Jun 26 01:54:31 UTC 2021
|
PRIMARY | |||
|
3753-81-9
Created by
admin on Sat Jun 26 01:54:31 UTC 2021 , Edited by admin on Sat Jun 26 01:54:31 UTC 2021
|
PRIMARY |
SUBSTANCE RECORD